↓ Skip to main content

Dove Medical Press

Article Metrics

Outcome of the HORIZONS-AMI trial: bivalirudin enhances long-term survival in patients with ST-elevation myocardial infarction undergoing angioplasty

Overview of attention for article published in Vascular Health and Risk Management, March 2012
Altmetric Badge

Mentioned by

twitter
1 tweeter

Readers on

mendeley
51 Mendeley
Title
Outcome of the HORIZONS-AMI trial: bivalirudin enhances long-term survival in patients with ST-elevation myocardial infarction undergoing angioplasty
Published in
Vascular Health and Risk Management, March 2012
DOI 10.2147/vhrm.s23491
Pubmed ID
Authors

Dmitriy Feldman, Shah

Abstract

Cardiovascular disease is the leading cause of death in the US. For patients with ST-elevation myocardial infarction (STEMI), urgent reperfusion of the culprit arterial occlusion, often achieved via primary percutaneous coronary intervention (PCI), reduces post-MI mortality and other major adverse cardiovascular events (MACE). Adjunctive antithrombotic and antiplatelet therapies are used during PCI to reduce MACE rates. Currently, a variety of antithrombotic options are available for peri-procedural use. The most commonly used agents include unfractionated heparin or low molecular weight heparin ± glycoprotein IIb/IIIa inhibitors (GPI). These agents reduce the rates of peri-procedural ischemic and thrombotic events, though these benefits come at the cost of an increase in bleeding complications. Bivalirudin is a direct thrombin inhibitor with a short half-life and linear pharmacokinetics, which results in predictable serum concentrations and anticoagulant effect. Bivalirudin has emerged as an efficacious and safe alternative to heparin plus GP IIb/IIIa inhibitors in both stable coronary artery disease and acute coronary syndrome patients. In the HORIZONS-AMI trial, monotherapy with bivalirudin was compared with the combination of heparin and a GPI in a large population of patients with STEMI who underwent primary PCI. Bivalirudin treatment was associated with improved event-free survival at 30 days and reduced rates of major bleeding. Based on the results of the trial, the American College of Cardiology/American Heart Association and European Society of Cardiology guidelines have incorporated recommendations for bivalirudin use in the setting of STEMI. Recently, 3-year follow-up data from the HORIZONS-AMI cohort were published, demonstrating sustained benefits in patients treated with bivalirudin, including reduced rates of mortality, cardiovascular mortality, reinfarction, and major bleeding events. These results further support the use of bivalirudin in the setting of primary PCI for STEMI given that its benefits are maintained through long-term follow-up.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 2%
Unknown 50 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 12 24%
Student > Ph. D. Student 7 14%
Student > Postgraduate 6 12%
Other 5 10%
Student > Master 5 10%
Other 11 22%
Unknown 5 10%
Readers by discipline Count As %
Medicine and Dentistry 34 67%
Agricultural and Biological Sciences 5 10%
Pharmacology, Toxicology and Pharmaceutical Science 2 4%
Economics, Econometrics and Finance 1 2%
Biochemistry, Genetics and Molecular Biology 1 2%
Other 2 4%
Unknown 6 12%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 February 2012.
All research outputs
#3,533,672
of 4,506,935 outputs
Outputs from Vascular Health and Risk Management
#264
of 314 outputs
Outputs of similar age
#58,535
of 75,175 outputs
Outputs of similar age from Vascular Health and Risk Management
#14
of 16 outputs
Altmetric has tracked 4,506,935 research outputs across all sources so far. This one is in the 2nd percentile – i.e., 2% of other outputs scored the same or lower than it.
So far Altmetric has tracked 314 research outputs from this source. They receive a mean Attention Score of 2.7. This one is in the 2nd percentile – i.e., 2% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 75,175 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.